Reuters logo
10 天前
BRIEF-Altimmune posts Q2 loss of $0.26 per share
2017年8月10日 / 早上6点59分 / 10 天前

BRIEF-Altimmune posts Q2 loss of $0.26 per share

Aug 10 (Reuters) - Altimmune Inc

* Altimmune announces second quarter 2017 financial results and provides corporate update

* Remains on track to initiate Phase 2 trial in Nasovax in Q3

* Altimmune Inc - expect to have sufficient resources to fund our current and planned development programs through key clinical milestones and 2Q 2018

* Qtrly net loss per share $0.26

* Altimmune - Quaterly revenue and grants and contracts were $3.0 million and $3.3 million, respectively, compared to $0.8 million and $1.3 million Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below